TradingKey – On October 9 ET, after Moderna (MRNA) was officially included in the Nasdaq 100 Index, its stock price once rose over 10%, hitting a recent high. As of press time, Moderna’s gain narrowed to 5.74%, trading at $208.31.

On the news front, Moderna has not yet published the full Phase 3 clinical trial results for its melanoma vaccine. Citi analyst Geoff Meacham pointed out that the market expects to see the data at the European Society for Medical Oncology (ESMO) Congress in Madrid later this month.

Bank of America analyst Alec Stranahan called the relevant results a “watershed moment.” In his view, this progress could help Moderna reduce its reliance on the infectious disease business and ease the company’s long-standing capital…